User:MallardTV/sandbox

From Wikipedia, the free encyclopedia

MallardTV/sandbox

Structural formula of insulin aspart
Vial of NovoRapid (insulin aspart)
Clinical data
Trade names	Novolog, Novorapid, Fiasp, others
AHFS/Drugs.com	Monograph
MedlinePlus	a605013
License data	US DailyMed: Insulin aspart
Pregnancy category	AU: A[1]
Routes of administration	Subcutaneous, intravenous
ATC code	A10AB05 (WHO )
Legal status
Legal status	AU: S4 (Prescription only)[2] CA: ℞-only [3] [4] UK: POM (Prescription only) EU: Rx-only In general: ℞ (Prescription only)
Pharmacokinetic data
Onset of action	15 minutes
Duration of action	3–5 hours
Identifiers
CAS Number	116094-23-6 [5]
PubChem CID	16132418
DrugBank	DB01306
UNII	D933668QVX
KEGG	D04475
ChEMBL	ChEMBL1201496
Chemical and physical data
Formula	C256H381N65O79S6
Molar mass	5825.60 g·mol−1

Insulin aspart is a rapid-acting analogue of human insulin used to improve glycemic control in people with type 1 and type 2 diabetes. Administered by subcutaneous injection shortly before meals, it mimics the body’s natural insulin response to food intake more effectively than regular human insulin. It has a faster onset—around 15 minutes—and a shorter duration of action, typically 3 to 5 hours. It reaches peak activity at around 30–90 minutes after administration.^[6] In many treatment regimens, it is combined with a longer-acting insulin to maintain baseline insulin levels. Insulin aspart is sold under several brand names, including NovoLog, NovoRapid, and Fiasp,^[6] and is also available in combination products such as NovoLog Mix 70/30.^[7] It can be delivered using insulin pens, pumps,^[8] or injection ports.

The medication is structurally similar to human insulin, differing by a single amino acid substitution—proline is replaced with aspartic acid at position B28—which allows for faster absorption following injection.^[9] It is manufactured through recombinant DNA technology in genetically modified strains of Saccharomyces cerevisiae (baker’s yeast),^[10] which produce the insulin analogue in fermentation systems.^[11] The drug was first approved for use in the United States in 2000 and has since become widely prescribed, ranking among the top 100 most common medications, with over eight million prescriptions issued in the U.S. alone in 2022.^[12]

Insulin aspart is generally well tolerated, with hypoglycemia being the most frequently reported side effect. Other potential adverse effects include injection site reactions, allergic responses, lipodystrophy (abnormal fat distribution at the injection site), weight gain, and fluid retention. Its safety profile is similar to that of regular insulin, and it is considered safe to use during pregnancy and breastfeeding. The drug exerts its effect by stimulating cellular uptake of glucose and suppressing hepatic (liver-produced) glucose production, thereby lowering blood glucose concentrations.

In addition to its original formulations, faster-acting versions such as Fiasp have been developed to improve postprandial (after-meal) glucose control, and several biosimilars—such as Merilog, Trurapi, Truvelog, and Kirsty—have been approved in various countries beginning in 2020. These alternatives offer comparable efficacy and safety and are part of broader efforts to increase access to insulin therapy.^[13]

Insulin aspart is indicated for the treatment of diabetes mellitus in both adults and children, including type 1 and type 2 diabetes. As a rapid-acting insulin analog, it is primarily used to control postprandial blood glucose levels. Its fast onset and short duration of action make it particularly suitable for use around mealtimes, often administered immediately before eating. Insulin aspart is typically prescribed as part of a basal–bolus insulin regimen, in which a long-acting insulin provides continuous background insulin coverage, while insulin aspart is used to counter the rise in glucose that occurs after food intake. This strategy aims to replicate the natural insulin secretion pattern of a healthy pancreas more closely than regimens using regular human insulin.

In people with type 1 diabetes, insulin aspart is often initiated at diagnosis and remains a foundational component of intensive insulin therapy throughout the individual's life. It allows for more precise and flexible control of blood glucose than older insulins due to its quicker onset and more predictable pharmacodynamic profile. In type 2 diabetes, insulin aspart may be introduced when lifestyle interventions and oral hypoglycemic agents no longer provide adequate glycemic control. It is especially useful in managing postprandial hyperglycemia and is often combined with a basal insulin or with premixed formulations like insulin aspart protamine to reduce the number of daily injections.

The medication is administered by subcutaneous injection, typically using insulin pens, prefilled devices, or traditional syringes, and can also be delivered via continuous subcutaneous insulin infusion (CSII) pumps, which allow for finer adjustments and convenience in intensive therapy. In hospital settings, insulin aspart may be given by intravenous infusion for acute glycemic management, particularly in surgical or critically ill patients where rapid insulin action is needed.

Insulin aspart is approved for use in pediatric populations, with dosage and timing tailored to the child’s age, weight, and meal patterns. It is also considered safe during pregnancy and breastfeeding, and is often used in pregnant individuals with preexisting diabetes or gestational diabetes when insulin therapy is required. To minimize adverse effects such as lipodystrophy, patients are advised to rotate injection sites within the same body region. Proper injection technique and adherence to prescribed timing are essential for achieving optimal blood glucose control and avoiding hypoglycemic episodes.

Insulin aspart functions as a synthetic analogue of human insulin, designed to facilitate glucose uptake into tissues and suppress hepatic glucose production, thereby reducing blood glucose levels. It binds to insulin receptors on the surface of target cells such as muscle and fat cells, initiating a signaling cascade that leads to the translocation of GLUT4 glucose transporters to the cell membrane. This enhances the rate of glucose entry into cells, where it can be used for energy or stored as glycogen. At the same time, insulin aspart inhibits gluconeogenesis and glycogenolysis in the liver, contributing to an overall reduction in circulating glucose levels.

The structural modification that differentiates insulin aspart from regular human insulin is a single amino acid substitution—proline at position B28 is replaced with aspartic acid.^[9] This change reduces the tendency of insulin molecules to self-associate into hexamers in solution, thereby allowing insulin aspart to remain primarily in monomeric form after injection. As a result, it is absorbed more quickly from subcutaneous tissue into the bloodstream, producing a faster onset of action. Despite this modification, insulin aspart retains full biological activity at the insulin receptor and produces metabolic effects equivalent to endogenous insulin.

After subcutaneous injection, insulin aspart begins to act within approximately 15 minutes, with peak activity occurring between 45 and 90 minutes. Its effects typically persist for 3 to 5 hours, making it suitable for managing prandial glucose excursions. The rapid onset and shorter duration of action make it more predictable than regular human insulin, which has a slower onset and longer duration due to its higher degree of self-association and delayed absorption. When delivered intravenously, insulin aspart acts almost immediately, but this route is typically reserved for hospital use in controlled settings.

Pharmacokinetic parameters may vary slightly based on factors such as injection site, skin temperature, local blood flow, and whether the insulin is used in an insulin pump or with an injection pen. In continuous subcutaneous infusion systems (insulin pumps), insulin aspart provides a steady basal rate with customizable boluses, offering fine-tuned control over blood glucose levels. The drug is eliminated primarily via renal metabolism after degradation by insulinases in the liver and kidneys, and no active metabolites have been identified. Its duration of action may be prolonged in individuals with renal impairment or reduced in cases of high insulin resistance.

Insulin aspart is primarily administered by subcutaneous injection, which enables rapid absorption and is well suited for routine outpatient management. It is typically delivered using prefilled disposable pens, reusable pen systems with cartridges, or traditional syringes, allowing for flexibility in dosing and ease of use. Common injection sites include the abdomen, thigh, upper arm, and buttocks, each with slightly different absorption kinetics. The abdomen generally provides the fastest absorption, making it the preferred site for pre-meal dosing, while the thigh and buttock offer slower uptake and may be used for basal or less time-sensitive injections. To reduce the risk of lipodystrophy and ensure consistent insulin absorption, patients are advised to rotate injection sites within the same body region rather than switching between regions.

Insulin aspart is also widely used in continuous subcutaneous insulin infusion (CSII) via insulin pumps, which provide a programmable basal rate and bolus doses to cover meals and correct hyperglycemia. This delivery method allows for more precise and dynamic insulin dosing and is commonly employed in intensive insulin therapy, particularly for individuals with type 1 diabetes who require fine-tuned glycemic control. Insulin aspart is compatible with most commercially available pump systems and is valued for its rapid onset, which closely mimics physiological insulin response to food intake.

In hospital or critical care settings, insulin aspart may be administered intravenously for the management of acute hyperglycemia, especially in surgical patients or those who are critically ill. When given intravenously, insulin aspart acts almost immediately, making it effective in situations requiring tight glycemic control and rapid glucose reduction. However, this route is reserved for controlled environments under medical supervision due to the need for frequent monitoring and dose adjustments

The most common and clinically significant adverse effect of insulin aspart is hypoglycemia, which may occur when the administered dose exceeds the individual’s current physiological insulin requirement. Symptoms of mild hypoglycemia include shakiness, dizziness, sweating, hunger, and confusion, while more severe episodes can result in seizures, loss of consciousness, or death if not promptly treated. The risk of hypoglycemia is influenced by factors such as meal timing, physical activity, concurrent illness, and incorrect insulin administration. As with all insulin therapies, proper patient education and blood glucose monitoring are essential to mitigate this risk.

Other frequently reported side effects include injection site reactions, such as redness, swelling, pain, and itching. These reactions are generally mild and transient but may persist or worsen in cases of poor injection technique or repeated use of the same site. Long-term subcutaneous administration of insulin aspart may lead to lipodystrophy, a condition characterized by localized loss or thickening of subcutaneous fat at injection sites. To reduce this risk, patients are advised to rotate injection locations within the same body region. Additionally, weight gain is a recognized side effect of insulin therapy, often resulting from improved glycemic control, decreased glucosuria, and the anabolic properties of insulin itself.

More serious but less common adverse effects include allergic reactions, ranging from localized hypersensitivity to systemic manifestations such as urticaria, angioedema, or anaphylaxis. True insulin allergies are rare, particularly with recombinant human analogs like insulin aspart, but they require prompt medical evaluation and alternative treatment if severe. Hypokalemia—a drop in serum potassium levels—can also occur, particularly with high insulin doses or in patients receiving insulin intravenously. This is due to insulin’s effect of driving potassium into cells along with glucose, which can lead to muscle weakness, arrhythmias, or cardiac arrest in extreme cases.

Overall, the safety profile of insulin aspart is considered comparable to that of regular human insulin, with no unique or unexpected toxicities. It is generally regarded as safe for use in pregnancy and breastfeeding, with no evidence of teratogenicity or adverse outcomes in neonates when used appropriately.

Insulin aspart is available in several formulations tailored to different therapeutic needs, modes of administration, and patient preferences. The standard formulation consists of a clear, colorless solution of insulin aspart intended for subcutaneous injection. It is typically supplied in vials, prefilled disposable pens, or cartridges compatible with reusable insulin pens. These delivery systems facilitate flexible dosing and enhance ease of use, particularly for individuals requiring multiple daily injections. The insulin can be administered in the abdomen, thigh, buttock, or upper arm, with absorption rates varying slightly by injection site. Insulin aspart is also approved for intravenous administration in clinical settings, though this route is generally limited to acute care environments under professional supervision.

In addition to its standard form, insulin aspart is available in premixed formulations that combine rapid- and intermediate-acting components to simplify insulin regimens. The most widely used is NovoLog Mix 70/30 (marketed as NovoMix 30 in some regions), which contains 30% soluble insulin aspart and 70% insulin aspart protamine. The protamine component prolongs the duration of action by delaying absorption, thereby serving as a basal insulin replacement. This biphasic formulation enables patients to receive both mealtime and background insulin coverage in a single injection, typically administered twice daily before meals. It is especially popular in type 2 diabetes management where simpler regimens are preferred.

A faster-acting formulation of insulin aspart, marketed as Fiasp, incorporates additional excipients such as niacinamide (vitamin B3) to accelerate initial absorption. Fiasp begins acting within 4 to 8 minutes of subcutaneous injection, providing even closer approximation to physiological insulin secretion in response to food intake. It can be used interchangeably with standard insulin aspart in insulin pumps and injection regimens, with dose adjustments based on individual response. Clinical studies have shown that Fiasp improves postprandial glucose control without significantly increasing the risk of hypoglycemia or glycemic variability.

Since the original approval of insulin aspart by regulatory agencies—beginning with the United States in 2000—several biosimilar versions have been developed and authorized for clinical use to increase affordability and access. A biosimilar is a biological product that is highly similar to an already approved reference product, with no clinically meaningful differences in terms of safety, purity, or potency. These medications are rigorously evaluated to ensure comparable quality and efficacy, although they are not identical due to the complex nature of biologic manufacturing.

The first insulin aspart biosimilar to receive U.S. Food and Drug Administration (FDA) approval was Merilog (insulin aspart-szjj), authorized in February 2025. Marketed in prefilled pen and vial formats, Merilog was developed by Sanofi-Aventis and is considered interchangeable with NovoLog, the reference product. Other biosimilars have been approved in different jurisdictions under various names, including Kirsty (formerly Kixelle) in the European Union and Canada, and Trurapi and Truvelog in Australia and Canada. These biosimilars are generally approved for use in the same patient populations and indications as the original formulation, and they are available in similar devices and delivery systems.

In addition to biosimilars, a notable alternative formulation is fast-acting insulin aspart, marketed as Fiasp. Though not a biosimilar, Fiasp is a modified version of insulin aspart that includes niacinamide to enhance the rate of absorption. It is intended for patients who require tighter postprandial glucose control and is particularly useful in pump therapy and multiple daily injection regimens. Fiasp has shown modest but clinically meaningful benefits in controlling early post-meal glucose spikes when compared to standard insulin aspart, with no significant increase in the incidence of hypoglycemia.

Despite the availability of biosimilars and advanced analogs, studies have shown mixed evidence regarding the superiority of insulin aspart over regular human insulin in type 2 diabetes, especially considering cost-effectiveness. However, in type 1 diabetes, insulin aspart and its biosimilar or fast-acting counterparts appear to offer slightly improved glycemic control, particularly in reducing postprandial hyperglycemia and improving treatment flexibility.

The development of insulin aspart is part of a broader history of insulin therapy that began in the early 20th century. The first successful insulin treatment was administered in 1922, following the discovery of insulin by Frederick Banting and Charles Best in 1921. Early insulin preparations were extracted from animal pancreases, typically bovine or porcine, and while lifesaving, they were associated with variable purity, immunogenic reactions, and inconsistent pharmacokinetics. The introduction of recombinant human insulin in the 1980s, produced using genetically modified bacteria or yeast, marked a major advance by reducing immunogenicity and improving manufacturing consistency. However, even recombinant human insulin had limitations, particularly its relatively slow onset and prolonged action after subcutaneous injection. These properties made it difficult to precisely match insulin availability to the body’s needs around meals. To address this, researchers in the 1990s began developing rapid-acting insulin analogs, including insulin lispro, insulin aspart, and insulin glulisine, by modifying the amino acid sequence of the insulin molecule to enhance absorption and better mimic physiological insulin secretion.

Insulin aspart was first approved for medical use in the United States in 2000, under the brand name NovoLog, manufactured by Novo Nordisk. It quickly became one of the most commonly prescribed rapid-acting insulin analogs and has remained widely used across many countries due to its reliable profile, flexibility in dosing, and compatibility with a variety of insulin delivery devices. Approval followed in the European Union and other jurisdictions, often under the brand name NovoRapid. In the following years, insulin aspart was integrated into a wide array of diabetes management protocols, particularly as part of basal–bolus insulin regimens and in continuous subcutaneous insulin infusion (CSII) systems.

Building on its success, manufacturers developed additional formulations to meet evolving clinical needs. One of the earliest was NovoLog Mix 70/30, a premixed insulin containing a longer-acting protamine-bound form of insulin aspart. This biphasic formulation allowed for simplified dosing regimens by combining both prandial and basal insulin activity in a single injection. Later, a faster-acting variant known as Fiasp was introduced. This version incorporated niacinamide to accelerate absorption and better match postprandial glucose excursions, marking a significant advancement in mimicking physiologic insulin secretion in real time.

In the 2020s, the global emphasis on expanding insulin access and reducing costs spurred the development of biosimilars to insulin aspart. Regulatory authorities such as the European Medicines Agency (EMA), Health Canada, Australia’s Therapeutic Goods Administration (TGA), and the FDA in the United States approved several biosimilar products, including Kirsty, Trurapi, Truvelog, and Merilog. The approval of Merilog in 2025 marked the first FDA-authorized biosimilar to insulin aspart in the United States and represented a milestone in insulin affordability. These developments reflect ongoing international efforts to address the cost burden of insulin while maintaining quality standards and therapeutic equivalence.

Insulin aspart is classified as a prescription-only medication in most countries. In the United States, it is regulated by the Food and Drug Administration (FDA) and is available by prescription only. In the European Union, it is designated as Rx-only and is approved under centralized or national procedures depending on the formulation. Similarly, in Canada, it is classified as a Schedule D drug and requires a prescription. In Australia, it is listed as a Schedule 4 (S4) substance under the Standard for the Uniform Scheduling of Medicines and Poisons, indicating that it is prescription-only. These classifications reflect the need for medical oversight in dosing, administration, and monitoring to ensure appropriate use and to reduce the risk of adverse effects, particularly hypoglycemia.

Since its initial approval, insulin aspart has become widely prescribed and is marketed under various brand names, including NovoLog, NovoRapid, and Fiasp. The medication is manufactured by Novo Nordisk and is distributed globally. The introduction of biosimilar products—such as Merilog, Kirsty, Trurapi, and Truvelog—has expanded access in several countries. These biosimilars are typically priced lower than the reference product and are intended to increase affordability while maintaining therapeutic equivalence. Despite the availability of biosimilars, access to insulin analogs remains a public health concern in many regions, particularly due to pricing variability, insurance coverage limitations, and regulatory barriers.

In the United States, insulin aspart has been the subject of broader discussions about insulin pricing and affordability. Advocacy groups and professional organizations have called for increased transparency and price regulation, particularly in light of the high cost of analog insulins relative to older formulations such as regular human insulin. Some manufacturers have responded by offering lower-cost options or co-pay assistance programs, though disparities in access remain.

Insulin aspart is a recombinant analog of human insulin that differs from the endogenous hormone by a single amino acid substitution. Specifically, the proline residue at position B28 of the B-chain is replaced with an aspartic acid.^[9] This modification reduces the molecule’s tendency to form hexamers in solution, allowing it to remain predominantly in a monomeric state after subcutaneous injection. As a result, insulin aspart is absorbed more rapidly than regular human insulin, producing a faster onset of action while retaining full biological activity at the insulin receptor.

The molecular formula of insulin aspart is C256H381N65O79S6, and its molar mass is approximately 5825.6 g/mol. It is composed of 51 amino acids arranged in two polypeptide chains—A and B—linked by disulfide bridges, similar to native insulin. The structural integrity and receptor-binding properties are preserved despite the B28 substitution, allowing insulin aspart to engage insulin receptors and initiate the same intracellular signaling pathways that promote glucose uptake and inhibit hepatic glucose production.

Production of insulin aspart involves recombinant DNA technology, using genetically engineered strains of Saccharomyces cerevisiae (baker’s yeast). The gene encoding the modified insulin is inserted into the yeast genome, allowing the host cells to synthesize the insulin precursor during fermentation.^[10] The product is then harvested, purified, and subjected to enzymatic processing to yield the final active form.^[11] Rigorous quality control measures are applied throughout manufacturing to ensure consistency, purity, and bioactivity in compliance with regulatory standards for biologic medicines.

Insulin aspart is formulated as a clear, colorless aqueous solution at a concentration of 100 units/mL (U-100), buffered with various excipients such as glycerol, phenol, metacresol, and zinc to maintain stability and isotonicity. In premixed formulations like NovoLog Mix 70/30, part of the insulin aspart is complexed with protamine to delay absorption, resulting in biphasic pharmacokinetics suitable for combination basal–bolus therapy. Variants such as Fiasp include additional excipients (e.g., niacinamide and L-arginine) to further accelerate absorption.

Several clinical studies have evaluated insulin aspart in comparison to regular human insulin and other rapid-acting analogs, focusing on efficacy, safety, and glycemic outcomes in both type 1 and type 2 diabetes. In individuals with type 1 diabetes, insulin aspart has demonstrated modest improvements in postprandial glucose control and overall glycemic variability when used as part of a basal–bolus regimen or delivered via continuous subcutaneous insulin infusion (CSII). These improvements are attributed to the faster onset of action of insulin aspart, which more closely mimics physiological insulin secretion following meals. Meta-analyses have generally supported its use as a first-line rapid-acting analog in intensive insulin therapy.

In type 2 diabetes, the clinical benefits of insulin aspart over regular human insulin are less pronounced. A Cochrane review concluded that while short-acting analogs like insulin aspart may slightly improve postprandial glucose levels, they offer no clear advantage in terms of long-term outcomes such as HbA1c reduction or risk of hypoglycemia. The relatively higher cost of analog insulins has led some researchers to question the routine replacement of regular insulin with insulin aspart in type 2 diabetes, particularly when cost-effectiveness is a major concern. Nevertheless, insulin aspart remains widely used in this population, often in combination with long-acting insulins or in premixed formulations.

Research has also focused on formulation improvements. A faster-acting version of insulin aspart, marketed as Fiasp, has been developed to further reduce the lag between injection and insulin action. Clinical trials have shown that Fiasp achieves earlier onset and improved postprandial glucose control without significantly increasing the risk of hypoglycemia. These characteristics have made it particularly useful in settings requiring tight glycemic control, such as insulin pump therapy and pregnancy. Additional studies continue to assess the long-term impact of fast-acting analogs on glycemic outcomes, quality of life, and treatment adherence.

With the increasing availability of biosimilar insulin aspart products, research has expanded to include comparative effectiveness and immunogenicity studies. These trials are designed to confirm that biosimilars match the reference product in terms of clinical performance, safety, and patient acceptability. Regulatory agencies require robust analytical and clinical data before approving biosimilars, and current evidence supports the therapeutic equivalence of several biosimilar versions now in use in the United States, Europe, and other regions.

• Biopharmaceutical
• Essential medicines
• Drug patent
• List of commercially available insulins

Retrieved from "https://en.wikipedia.org/w/index.php?title=User:MallardTV/sandbox&oldid=1296625461"